M
Mb1925
Guest
| Line 9: | Line 9: |
| Line 16: | Line 17: |
[td]
β Previous revision
[/td][td]
[td]| native_name = {{nobold|ιΊζ²ζ}}[/td]Revision as of 15:13, 1 September 2025
[/td][td]| native_name = {{nobold|ιΊζ²ζ}}[/td] [td]| native_name_lang = zh-hk[/td]
[td]| native_name_lang = zh-hk[/td] [td]| alma_mater = [[University of Hong Kong]][/td]
[td]| alma_mater = [[Wah Yan College, Kowloon]][/td] [td][[University of Hong Kong]][/td] [td]| thesis_title = Cytogenetics and molecular genetics of haematological disorders[/td]
[td]| thesis_title = Cytogenetics and molecular genetics of haematological disorders[/td] [td]| thesis_url = https://hub.hku.hk/handle/10722/26588[/td]
[td]| thesis_url = https://hub.hku.hk/handle/10722/26588[/td] [td]| field = [[Haematology]][/td]
[td]| field = [[Haematology]][/td] [td]| known_for = Research on[/td]
[td]| known_for = Research on[/td] [td][[Arsenic Trioxide|Oral Arsenic Trioxide]], [[Acute Promyelocytic Leukemia|Acute Promyelocytic Leukaemia]], [[T-cell lymphoma]], [[Hematopoietic stem cell transplantation]], [[CAR-T]][/td] [td][[Arsenic]][/td] [td][[Leukemia]][/td] [td][[Hematopoietic stem cell transplantation]][/td] [td]| website = https://medic.hku.hk/en/Staff/Unive...Prof-KWONG-Yok-Lam/Prof-KWONG-Yok-Lam-Profile[/td]
[td]| website = https://medic.hku.hk/en/Staff/Unive...Prof-KWONG-Yok-Lam/Prof-KWONG-Yok-Lam-Profile[/td] [td]}}[/td]
[td]}}[/td] [td][/td]
[td][/td] [td]'''Kwong Yok Lam''' ({{lang-zh|t=ιΊζ²ζ||first=t}}) is a [[Hong Kong]] [[Hematology|hematologist]]. Kwong is the Chief of the Division of Haematology, Oncology and Bone Marrow Transplantation at the Department of Medicine, School of Clinical Medicine, the [[University of Hong Kong]]. He specialises in haematology and haematopathology. His clinical work focuses on the management of haematological malignancies. His research centers on the molecular pathogenetic pathways and novel treatment modalities in haematological neoplasms. Kwong has pioneered the development and use of oral [[arsenic trioxide]] in the treatment of [[Acute promyelocytic leukemia|acute promyelocytic leukaemia]] and other blood cancers.<ref>{{Cite web |title=Yok Lam Kwong |url=https://croucher.org.hk/en/fellows-and-scholars/kwong-yok-lam |access-date=2025-02-06 |website=Croucher Foundation |language=en}}</ref>[/td]
[td]'''Kwong Yok Lam''' ({{lang-zh|t=ιΊζ²ζ||first=t}}) is a [[Hong Kong]] [[Hematology|haematologist]]. Prof Kwong is the Chair Professor and Chief of the Division of Haematology, Oncology and Bone Marrow Transplantation at the Department of Medicine, School of Clinical Medicine, the [[University of Hong Kong]]. He specialises in haematology and haematopathology. His clinical work focuses on the management of haematological malignancies. His research centres on the molecular pathogenetic pathways and novel treatment modalities in a variety of haematological neoplasms. Prof Kwong has pioneered the development and use of oral [[arsenic trioxide]] in the treatment of [[Acute promyelocytic leukemia|acute promyelocytic leukaemia]] and other blood cancers.<ref>{{Cite web |title=Yok Lam Kwong |url=https://croucher.org.hk/en/fellows-and-scholars/kwong-yok-lam |access-date=2025-02-06 |website=Croucher Foundation |language=en}}</ref>[/td] [td][/td]
[td][/td] [td]== Career ==[/td]
[td]== Career ==[/td] [td]Kwong graduated from the [[Li Ka Shing Faculty of Medicine|Faculty of Medicine at the University of Hong Kong]] with an MBBS in 1983. He then received his MRCP in 1986; MRCPath in 1991; FHKCP, FHKAM(Medicine), FHKCPath, FHKAM(Pathology) in 1993; MD(HK) in 1995, and FRCP(Edin) in 1997.{{cn|date=May 2025}}[/td]
[td]Kwong graduated from [[Wah Yan College, Kowloon]] in 1976. He obtained his MBBS degree with honours from the [[Li Ka Shing Faculty of Medicine|Faculty of Medicine of the University of Hong Kong]] at the top of his class with the John Anderson Gold Medal, CP Fong Gold Medal in Medicine, Digby Memorial Gold Medal in Surgery, Nesta and John Gray Gold Medal in Surgery, and Gordon King Prize in Obstetrics and Gynaecology in 1983.<ref>{{Cite web |title=Elixir 1983 |url=https://hub.hku.hk/bitstream/10722/138789/15/B46509422-1983.pdf|access-date=2025-09-01 |website=Elixir 1983 |language=en}}</ref> He then received his MRCP in 1986; FRCPath in 1991; FHKCP, FHKAM (Medicine), FHKCPath, and FHKAM (Pathology) in 1993; MD (HK) in 1995, and FRCP (Edin) in 1997.<ref>{{Cite web |title=KWONG YOK LAM |url=https://www.thkma.org/our_works/01060/ |access-date=2025-09-01 |website=The Hong Kong Medical Association |language=en}}</ref>[/td] [td][/td]
[td][/td] [td]Kwong Yok-lam, in collaboration with Professor Cyrus Kumana, developed an innovative treatment for acute promyelocytic leukaemia at the University of Hong Kong. This oral arsenic-based drug, [[Medical use of arsenic trioxide|arsenic trioxide]], created without external funding, has shown remarkable success with a cure rate of 98.2%. The treatment, safer and more cost-effective than intravenous arsenic, has replaced traditional bone marrow transplants in Hong Kong. This breakthrough marks Hong Kong's first drug invention.<ref>{{Cite web |title=HKU Bulletin |url=https://www4.hku.hk/pubunit/Bulletin/2010_Aug_Vol.11_No.3/research/page5.html |access-date=2025-02-06 |website=www4.hku.hk}}</ref>[/td]
[td]Kwong Yok-lam, in collaboration with Professor Cyrus Kumana, developed an innovative treatment for acute promyelocytic leukaemia at the University of Hong Kong. This oral arsenic-based drug, [[Medical use of arsenic trioxide|arsenic trioxide]], created without external funding, has shown remarkable success with a cure rate of 98.2%. The treatment, safer and more cost-effective than intravenous arsenic, has replaced traditional bone marrow transplants in Hong Kong. This breakthrough marks Hong Kong's first drug invention.<ref>{{Cite web |title=HKU Bulletin |url=https://www4.hku.hk/pubunit/Bulletin/2010_Aug_Vol.11_No.3/research/page5.html |access-date=2025-02-06 |website=www4.hku.hk}}</ref>[/td]
Continue reading...
